BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 11420729)

  • 1. The Rb/chromatin connection and epigenetic control: opinion.
    Ferreira R; Naguibneva I; Pritchard LL; Ait-Si-Ali S; Harel-Bellan A
    Oncogene; 2001 May; 20(24):3128-33. PubMed ID: 11420729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinoblastoma protein recruits histone deacetylase to repress transcription.
    Brehm A; Miska EA; McCance DJ; Reid JL; Bannister AJ; Kouzarides T
    Nature; 1998 Feb; 391(6667):597-601. PubMed ID: 9468139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinoblastoma protein represses transcription by recruiting a histone deacetylase.
    Magnaghi-Jaulin L; Groisman R; Naguibneva I; Robin P; Lorain S; Le Villain JP; Troalen F; Trouche D; Harel-Bellan A
    Nature; 1998 Feb; 391(6667):601-5. PubMed ID: 9468140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters.
    Robertson KD; Ait-Si-Ali S; Yokochi T; Wade PA; Jones PL; Wolffe AP
    Nat Genet; 2000 Jul; 25(3):338-42. PubMed ID: 10888886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Histone deacetylase and retinoblastoma protein].
    Magnaghi-Jaulin L; Groisman R; Naguibneva I; Robin P; Trouche D; Harel-Bellan A
    Bull Cancer; 1998 Jul; 85(7):606-7. PubMed ID: 9752266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The p107 tumor suppressor induces stable E2F DNA binding to repress target promoters.
    O'Connor RJ; Schaley JE; Feeney G; Hearing P
    Oncogene; 2001 Apr; 20(15):1882-91. PubMed ID: 11313936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CBP/p300 histone acetyl-transferase activity is important for the G1/S transition.
    Ait-Si-Ali S; Polesskaya A; Filleur S; Ferreira R; Duquet A; Robin P; Vervish A; Trouche D; Cabon F; Harel-Bellan A
    Oncogene; 2000 May; 19(20):2430-7. PubMed ID: 10828885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action.
    Markey MP; Angus SP; Strobeck MW; Williams SL; Gunawardena RW; Aronow BJ; Knudsen ES
    Cancer Res; 2002 Nov; 62(22):6587-97. PubMed ID: 12438254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional repression. The cancer-chromatin connection.
    DePinho RA
    Nature; 1998 Feb; 391(6667):533, 535-6. PubMed ID: 9468130
    [No Abstract]   [Full Text] [Related]  

  • 10. Rb dephosphorylation and suppression of E2F activity in human breast tumor cells exposed to a pharmacological concentration of estradiol.
    Gewirtz DA; Di YM; Randolph JK; Jain PT; Valerie K; Bullock S; Nath N; Chellappan SP
    Arch Biochem Biophys; 2001 Apr; 388(2):243-52. PubMed ID: 11368161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression analysis using DNA microarrays demonstrates that E2F-1 up-regulates expression of DNA replication genes including replication protein A2.
    Kalma Y; Marash L; Lamed Y; Ginsberg D
    Oncogene; 2001 Mar; 20(11):1379-87. PubMed ID: 11313881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(ADP-ribose) polymerase upregulates E2F-1 promoter activity and DNA pol alpha expression during early S phase.
    Simbulan-Rosenthal CM; Rosenthal DS; Luo R; Smulson ME
    Oncogene; 1999 Sep; 18(36):5015-23. PubMed ID: 10490838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel pRb binding sites using CpG microarrays suggests that E2F recruits pRb to specific genomic sites during S phase.
    Wells J; Yan PS; Cechvala M; Huang T; Farnham PJ
    Oncogene; 2003 Mar; 22(10):1445-60. PubMed ID: 12629508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of pRB-family/E2F complex in the inhibition of IL-3-dependent lymphoid cell proliferation.
    Yamada M; Kondo T; Ashizawa S; Takebayashi T; Higashi H; Hatakeyama M
    Cytokine; 2002 Jan; 17(2):91-7. PubMed ID: 11886176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rb/E2F: a two-edged sword in the melanocytic system.
    Halaban R
    Cancer Metastasis Rev; 2005 Jun; 24(2):339-56. PubMed ID: 15986142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E2F target genes and cell-cycle checkpoint control.
    Lavia P; Jansen-Dürr P
    Bioessays; 1999 Mar; 21(3):221-30. PubMed ID: 10333731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function.
    Wang S; Nath N; Adlam M; Chellappan S
    Oncogene; 1999 Jun; 18(23):3501-10. PubMed ID: 10376528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The retinoblastoma gene: from its basic understanding as a signal mediator for growth and differentiation to its use in the treatment of cancer].
    Lee WH; Lee EY
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1368-80. PubMed ID: 9309128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pRB phosphorylation mutants reveal role of pRB in regulating S phase completion by a mechanism independent of E2F.
    Chew YP; Ellis M; Wilkie S; Mittnacht S
    Oncogene; 1998 Oct; 17(17):2177-86. PubMed ID: 9811449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-2-induced changes in E2F regulatory complexes reveal the potential for integrated cell cycle and cell death functions.
    Lind EF; Wayne J; Wang QZ; Staeva T; Stolzer A; Petrie HT
    J Immunol; 1999 May; 162(9):5374-9. PubMed ID: 10228014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.